SCHEMBL4176983

SCHEMBL4176983

COc1ccc(Nc2nnc(-c3cccnc3N(C)c3ccc4c(c3)OCO4)o2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.52
FLT1 P17948 1/20 0.52
TUBB4A P04350 14/20 0.49
TUBB P07437 14/20 0.49
TUBA3C P0DPH7 14/20 0.49
TUBA1B P68363 14/20 0.49
TUBA4A P68366 14/20 0.49
TUBB4B P68371 14/20 0.49
TUBB3 Q13509 14/20 0.49
TUBB2A Q13885 14/20 0.49
TUBB8 Q3ZCM7 14/20 0.49
TUBA3E Q6PEY2 14/20 0.49
TUBA1A Q71U36 14/20 0.49
TUBA1C Q9BQE3 14/20 0.49
TUBB6 Q9BUF5 14/20 0.49
TUBB2B Q9BVA1 14/20 0.49
TUBB1 Q9H4B7 14/20 0.49
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4168532 0.89 TUBB4A (0.61) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4182058 0.88 KDR (0.52) KDRFLT1TUBB4ATUBBTUBA3C
SCHEMBL4177533 0.83 KDR (0.51) KDRFLT1TUBB4ATUBBTUBA3C
SCHEMBL4176979 0.79 TUBB4A (0.78) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4174177 0.77 TUBB4A (0.78) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4181575 0.76 KIT (0.42) KDR
SCHEMBL4187672 0.73 TUBB4A (0.66) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4176986 0.73 KDR (0.52) KDRFLT1TUBB4ATUBBTUBA3C
SCHEMBL4174278 0.72 TUBB4A (0.82) KDRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4179205 0.72 TUBB4A (0.43) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed
WO-2005004818-A2 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL KDR 3284/4885FLT1 3408/4885TUBB4A 777/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL KDR 3284/4885FLT1 3408/4885TUBB4A 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.